Treatment and prevention of equine gastric ulcer syndrome.

This research explores the prevention and treatment methods for equine gastric ulcer syndrome (EGUS), a common disorder in horses. It investigates the efficacy of various therapies, highlighting that GastroGard and ranitidine have proven effective, although ranitidine’s treatment failure is often linked to inaccurate dosing and owners not fully adhering to the three-times-daily dosing schedule.

Understanding Equine Gastric Ulcer Syndrome (EGUS)

• EGUS is a prevalent ailment in horses and foals. The disorder is primarily caused by the effects of acids.
• Currently, the primary therapeutic approach to EGUS involves suppressing gastric HCl and fostering an environment conducive for the healing of ulcers.
• Diagnosis for EGUS is based on historical patterns, clinical symptoms, gastroscopy, and response to treatment methods.

Assessing Treatment Methods

• The study identifies GastroGard (an FDA approved medication) and ranitidine as medicines that have effectively treated EGUS.
• However, it points out ranitidine’s limitations. Its effectiveness is curbed due to common instances of incorrect dosage administration and insufficient owner compliance because of the demanding requirement of thrice-daily dosing.

EGUS Scenario in Critically Ill Neonatal Foals

• The research also notes that EGUS commonly manifests in critically ill neonatal foals.
• However, the formation and progression of the disorder might differ from those in mature horses, implying the potential for a varied therapeutic response.
• As such, the study suggests that the routine acid-suppressive treatment may not be as effective in treating EGUS in these young, critically ill foals.